Cardioprotection Afforded by SUR2A: An Update
Journal Title: Journal of Cardiobiology - Year 2013, Vol 1, Issue 2
Abstract
SUR2A is an atypical ABC protein serving as a regulatory subunit of ATP-sensitive K+ (KATP) channels. In experimental animals, it has been found that an increase in myocardial level of this protein protects the heart against different types of metabolic stresses, including ischaemia. Increase in SUR2A leads to increase in number of fully-assembled KATP channels, which is associated with earlier channel activation during ischaemia as well as increased production of ATP by enzymes that are physically associated with the channel subunits. Activation of KATP channels shorten action membrane potential to prevent Ca2+ influx while ATP production increases subsarcolemmal ATP levels providing energy for vital energydependent processes at this localisation. The most recent findings are that SUR2A might also regulate expression of genes that are important in cardioprotection. How to increase SUR2A expression in an efficient and safe manner has been considered. Two possible approaches have been found to be promising. One is gene therapy approach with adenovirus containing SUR2A which was successful at the cellular level and the other was oral nicotinamide, a form of vitamin B3, which was efficient under ex vivo conditions. Based on all these findings, we believe that SUR2A-based strategies against heart ischaemia deserve to be further elucidated and tested. A therapy of ischaemic heart disease exploiting endogenous cardioprotective factors, including SUR2A, would be an excellent adjunct to current therapeutic strategies of ischaemic heart disease and other cardiovascular diseases where increase in cardiac resistance to stress would be beneficial.
Authors and Affiliations
Aleksandar Jovanović
Keywords
Related Articles
- EP ID EP194344
- DOI 10.13188/2332-3671.1000001
- Views 81
- Downloads 0
Primary Thyroid Lymphoma: A Comprehensive Review of Contemporary Management
Primary thyroid lymphoma is an uncommon malignancy that constitutes fewer than 2% of all extranodal non-Hodgkin lymphomas (NHLs) and only 0.6% to 5% of all thyroid malignancies. Histologic subtypes include diffuse large...
CRT-P Implantation and Consecutive AV-node Ablation as Rescue Therapy for Refractory Atrial Fibrillation: A Single Center Experience
Aims: Cardiac resynchronization therapy (CRT-P) and atrioventricular node (AVN) ablation are a recommended treatment option for patients with atrial fibrillation (AF) refractory to medical treatment or pulmonary vein iso...
Assessment of Copper Status in Patients with Paroxysmal Atrial Fibrillation
Background: Recent research has demonstrated disturbances of copper balance in the development of cardiovascular diseases. Copper status in patients with atrial fibrillation is still unknown. Serum or plasma copper and c...
Cardioprotection Afforded by SUR2A: An Update
SUR2A is an atypical ABC protein serving as a regulatory subunit of ATP-sensitive K+ (KATP) channels. In experimental animals, it has been found that an increase in myocardial level of this protein protects the heart aga...
Outcome of Percutaneous Patent Foramen Ovale Closure with the Premere Occluder — A Single Center Experience
Introduction: Percutaneous closure of patent foramen ovale (PFO) has become a widely used procedure in patients with suspected paradoxical embolism. Despite being generally safe and effective, the minimally invasive inte...